



Shionogi to Announce Personnel Reassignment

OSAKA, Japan, August 29, 2024 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.) announced that Shionogi will implement the following personnel reassignment as of October 1, 2024.

Personnel Reassignments (Effective; October 1, 2024)

Name	New Position	Current Position
R&D Supervisory Unit		
Hirohide Nambu	Senior Director, R&D Supervisory Unit Office and Diagnostic Drug Office	Senior Director, R&D Supervisory Unit Office
Healthcare Business Supervisory Unit		
Integrated Disease Care Division		
Yosuke Mihar	Corporate Officer, Senior Vice President, Integrated Disease Care Division and President of Stream I Co., Ltd.	Corporate Officer, Senior Vice President, Integrated Disease Care Division, New Product Planning Department, and President of Stream I Co., Ltd.
Hiroaki Itoh	Vice President, New Product Planning Department	Ping An-Shionogi Co., Ltd.

the Diagnostics Business Office, which is in the Healthcare Business Supervisory Unit, will be placed directly under the R&D Supervisory Unit in order to strengthen collaboration with the research and development organization.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of

availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>